CompletedPhase 2NCT00606502
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Principal Investigator
- Garry Weems, PharmDSpectrum Pharmaceuticals, Inc
- Intervention
- Pralatrexate(drug)
- Enrollment
- 201 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2010
Study locations (30)
- Comprehensive Blood and Cancer Center, Bakersfield, California, United States
- Sharp Memorial Hospital, San Diego, California, United States
- Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- Donald Berdeaux, Great Falls, Montana, United States
- Summit Medical Group, Berkeley Heights, New Jersey, United States
- Hematology and Oncology Associates South Jersey, Mount Holly, New Jersey, United States
- New York Oncology Hematology-Oncology Associates, P.C., Latham, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- New Bern Cancer Care, New Bern, North Carolina, United States
- Signal Point Clinical Research Center, Middletown, Ohio, United States
- Baptist Regional Cancer Center, Knoxville, Tennessee, United States
- Cancer Therapy and Research Center, San Antonio, Texas, United States
- Providence Everett Medical Center, Everett, Washington, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00606502 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →